RPTP Share Price

Open 8.95 Change Price %
High 9.05 1 Day 0.00 0.00
Low 8.95 1 Week 0.00 0.00
Close 9.00 1 Month 0.00 0.00
Volume 753206 1 Year 2.94 48.51
52 Week High 9.05
52 Week Low 2.94
RPTP Important Levels
Resistance 2 9.09
Resistance 1 9.05
Pivot 9.00
Support 1 8.95
Support 2 8.91
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.70 0.20%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
RITT 0.06 -45.45%
More..

Raptor Pharmaceutical Corp. (NASDAQ: RPTP)

RPTP Technical Analysis 5
As on 24th Oct 2016 RPTP Share Price closed @ 9.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 5.71 & Strong Buy for SHORT-TERM with Stoploss of 8.17 we also expect STOCK to react on Following IMPORTANT LEVELS.
RPTP Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
RPTP Other Details
Segment EQ
Market Capital 225990480.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.raptorpharma.com
RPTP Address
RPTP
5 Hamilton Landing
Suite 160
Novato, CA 94949
United States
Phone: 415-408-6200
Fax: 415-382-8002
Interactive Technical Analysis Chart Raptor Pharmaceutical Corp. ( RPTP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Raptor Pharmaceutical Corp.
RPTP Business Profile
Raptor Pharmaceuticals Corp. (RPC), formerly TorreyPines Therapeutics, Inc., is an early development-stage Company. The Company�s product portfolio includes both candidates from its drug targeting platforms and in-licensed and acquired product candidates. As of August 31, 2010, its pipeline includes three clinical development programs. It also has three other clinical-stage product candidates, for which it is seeking business development partners, and it has four preclinical product candidates it is developing, three of which are based upon its drug-targeting platforms. As of August 31, 2010, the Company had no revenues. On September 29, 2009, the Company and its wholly owned subsidiary, ECP Acquisition, Inc., completed a reverse merger, business combination with RPC, pursuant to which RPC became its wholly owned subsidiary.